Jasper Therapeutics to Present Preclinical Briquilimab Data at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific MeetingGlobeNewsWire • 10/24/24
Why Is Chronic Disease-Focused Jasper Therapeutics Stock Trading Higher On Monday?Benzinga • 10/14/24
Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible UrticariaGlobeNewsWire • 10/14/24
Jasper Therapeutics Announces Health Canada Clearance of Clinical Trial Application for Phase 1b/2a Study of Briquilimab in AsthmaGlobeNewsWire • 09/10/24
Jasper Therapeutics to Present at Present at Upcoming September Investor ConferencesGlobeNewsWire • 09/04/24
Jasper Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate DevelopmentsGlobeNewsWire • 08/13/24
Jasper Therapeutics Announces Appointment of Svetlana Lucas Ph.D., to its Board of DirectorsGlobeNewsWire • 06/19/24
Jasper Therapeutics to Present at the Oppenheimer Novel Targets in Immunology SummitGlobeNewsWire • 06/17/24
Jasper Therapeutics Presents Data from Preclinical Briquilimab Study at the 2024 EHA Hybrid CongressGlobeNewsWire • 06/14/24
Jasper Therapeutics to Present Data on Briquilimab in Mast Cell Driven Diseases at the EAACI Congress 2024GlobeNewsWire • 05/30/24
Jasper Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate DevelopmentsGlobeNewsWire • 05/14/24
Jasper Therapeutics (JSPR) Upgraded to Buy: Here's What You Should KnowZacks Investment Research • 05/07/24
Jasper Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare ConferenceGlobeNewsWire • 04/02/24
Jasper Therapeutics (JSPR) Is a Great Choice for 'Trend' Investors, Here's WhyZacks Investment Research • 03/22/24
Jasper Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual ConferenceGlobeNewsWire • 03/21/24
Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible UrticariaGlobeNewsWire • 03/19/24
New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi AnemiaGlobeNewsWire • 03/15/24
Jasper Therapeutics, Inc. (JSPR) Is Up 24.77% in One Week: What You Should KnowZacks Investment Research • 03/14/24
Here's Why Momentum in Jasper Therapeutics, Inc. (JSPR) Should Keep goingZacks Investment Research • 03/06/24
Jasper Therapeutics Reports Fiscal 2023 Financial Results and Recent Corporate DevelopmentsGlobeNewsWire • 03/04/24
Jasper Therapeutics to Present at the 43rd Annual TD Cowen Healthcare ConferenceGlobeNewsWire • 02/26/24
Jasper Therapeutics Presents Data from Preclinical Briquilimab Studies at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual MeetingGlobeNewsWire • 02/23/24